Treats a deleterious BRCA mutation (germline and/or … primary peritoneal cancer. Sold as Rubraca. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Rucaparib Camsylate (sold as Rubraca), first approved Dec 19, 2016, with 7 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Rubraca | Part D | $33.4M | +6% | 409 |
| Study | Phase | Status | Posted |
|---|---|---|---|
| A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation TherapyCastration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma · Alliance for Clinical Trials in Oncology | Phase 3 | Active, not recruiting | Jul 2, 2020 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
